NasdaqGS:ZVRAPharmaceuticals
Is Zevra Therapeutics (ZVRA) Blending Niche Rare-Disease Focus With Mainstream Index Visibility Effectively?
In late June 2026, Zevra Therapeutics was added to a wide range of Russell value, growth, small-cap, and defensive indices, while also reporting new published clinical data on its approved Niemann-Pick disease type C therapy, MIPLYFFA (arimoclomol), in very young pediatric patients.
This combination of broader index inclusion and additional real-world clinical evidence for an ultra-rare disease treatment underscores how Zevra is increasingly intersecting with both specialized healthcare...